The World Health Organization (WHO) thymoma histological classification clinical value remains a controversy. In this study, we evaluated its prognostic significance in patients with thymoma treated with radical intent.
INTRODUCTION
Thymomas are uncommon low-grade thymic epithelial malignancies, which represent the most frequent anterior mediastinal tumours in adults. A thymoma's histology is characterized by wide heterogeneity and in the last 50 years several histopathological classifications have been proposed.
The first World Health Organization (WHO) thymoma histological classification is dated 1999 [1] ; the latest revision has been released in 2004 [2] . It recognizes two main thymoma types:
(1) Type A (so-called 'Medullary thymoma' in the previous MullerHermelink's classification [3] ): composed by neoplastic thymic epithelial cells having a spindle or oval shape, lack of nuclear atypia and companied by a few or no non-neoplastic lymphocytes. (2) Type B: composed of aspects of round and polygonal tumour cells. According to nuclear atypia and number of lymphocytes, Type B thymoma is separated into three subtypes: B1 ( predominantly cortical thymoma), resembling the normal functional thymus with large lymphocytic infiltrate, practically indistinguishable from normal thymic cortex; B2 (cortical thymoma) with less lymphocytic infiltrate and a neoplastic epithelial component that appears as scattered plump cells with vesicular nuclei and distinct nuclei; B3, with a minor component of lymphocytes and predominance of round or polygonal-shaped epithelial cells with no or mild atypia.
Tumours with combined areas of Types A and B are defined as AB thymomas.
Initially classified as Type C thymoma, thymic carcinoma is now listed separately, due to its different histological pattern (i.e. cytological atypia, invasiveness and cytoarchitectural features not thymus-specific) and aggressive clinical behaviour. Primary thymic neuroendocrine tumours are also listed in the thymic carcinoma group.
This classification is commonly adopted in clinical and pathological practice, but its usefulness and significance in predicting patient survival remains uncertain. The poor prognosis of thymic carcinomas (TC) and B3 thymomas has been widely accepted [4, 5] , while the predictive value of other histological subtypes of thymomas is still debated. In particular, several papers reported a significant impact of WHO classes on survival [6, 7] , although other authors [8] described a similar risk of death among the different histological subtypes. Moreover, most of this study are single-centre cases series, based only on 100-200 cases; besides, they were treated over a large period of time. Hence, clear indications about the WHO histological classification's clinical value are still not accurate.
In this retrospective multi-institutional study, we aim to assess the role of the WHO histological classification as a prognostic factor in a large cohort of 750 thymomas operated on in six highvolume Italian General Thoracic Surgery Institutions.
PATIENTS AND METHODS
All patients operated for thymic epithelial tumours (TET) at six highvolume Italian General Thoracic Surgery Institutions were included in this study. Datasets comprised records concerning patients clinics and demographics, presence of myasthenia gravis (MG), history of previous primary malignancies, type of surgical approach and resection, tumour size and invasiveness, Masaoka pathological stage, resection status, preoperative and adjuvant treatment.
Between 1990 and 2011, out of 811 patients with TET, 750 thymomas were identified and represent the population of this study. TC and primary neuroendocrine thymic tumours (NETTs) were excluded.
The preoperative work-up was comparable in all institutions and included routine blood tests, electrocardiography, echocardiography if required, pulmonary function tests with diffusion capacity, arterial blood gas analysis, neurological consultation to rule out MG, and chest and upper abdomen computed tomography (CT). Magnetic resonance was performed in the case of advanced lesions, to assess their possible invasion of the great vessels, heart, trachea or other mediastinal organs/structures.
The follow-up protocol, quite similar in all institutions, included CT scan every 6 months for the first 3 years, and afterwards on a yearly basis or on clinical demand.
Patients submitted to surgery before 2004 were reclassified according to the latest WHO-HC.
According to the International Thymic Malignancy Interest Group (ITMIG) standards, surgery was defined radical (R0) when a complete tumour resection was possible, and incomplete in case of microscopically (R1) or macroscopically (R2) residuals [9] .
Finally, since either Masaoka or Masaoka-Koga systems were used in different centres, the two staging systems were combined together for statistical analyses.
STUDY OUTCOMES
The ITMIG standard outcome measures were considered for this study [10] .
Primary outcomes were overall survival (OS), freedom from recurrence (FFR) and the cumulative incidence of recurrence (CIR). OS was calculated from the date of intervention to the date of death by any cause; patients alive were censored on the date of last follow-up. FFR was computed from the date of surgery to the date of recurrence or death (any cause). CIR was assessed from the date of surgery to the date of recurrence; patients alive or without recurrence were censored on the date of the last followup. OS was computed on the entire population, and FFR and CIR were evaluated only in case of complete (R0) resections and when complete data on recurrence status were available.
WHO-HC types was evaluated by two schemes: according to 2004 WHO-HC [2] (classic scheme) and collapsing histology subtypes in three categories: A/AB, B1/B2 (Early-B) and B3 (advanced B), as suggested by Wright et al. [11] .
Moreover, WHO histological type's significance in the collapsed scheme was presented as a linear increment (from A/AB to advanced-B).
Variables of interest considered for the analyses included: WHO-HC types (as previously explained), age at surgery (as continuous), gender (female as reference), MG (no vs yes), Masaoka stage (I/II as references), year of intervention (2006-2011 as reference), preoperative therapy (no vs yes), completeness of resection (R0 vs R1-R2), adjuvant therapy (no vs yes).
Finally, association between WHO histological types and variable of interest was evaluated.
STATISTICAL ANALYSIS
Categorical data are presented as number ( percentage, %), and continuous data as median [interquartile range, (IQR)]. OS and CIR were estimated using the Kaplan-Meier method. We used univariate and multivariate Cox models to evaluate possible predictors of survival. Competing-risk regression models (Fine and Gray), taking into account death by any cause as a competing event, were performed to identify the association between individual factors and FFR. Outcome heterogeneity by centres was investigated by applying the model extensions (shared frailty) for clustered data analysis.
Association between WHO-HC types and variables of interest was assessed using a multivariate logistic regression model. Odds ratio (OR) and the corresponding 95% confidence intervals (95% CIs) were provided for each model. All statistical analyses were performed using STATA (version 12.1).
RESULTS

Demographics and clinical characteristics
Patients' demographics and clinical characteristics are illustrated in Table 1 . Patients were mostly male (379, 59%), with a median age at surgery of 55 years (IQR: 22). Three hundred and sixty-three of them (48%) presented with MG. Thymomectomy was performed through a complete (569 cases) or partial (84) sternotomy or thoracotomy (63); in 9 cases a robot-assisted thoracic surgery (RATS), and in 1 a transcervical approach was done. In 22 cases a combined surgical approach was used (sternotomy plus thoracotomy). WHO histological subtypes were observed as follows: 109 (15%) A, 166 (22%) AB, 179 (24%) B1, 158 (21%) B2 and 135 (18%) B3.
One-hundred and five patients (14%) received a preoperative treatment and 438 (58%) an adjuvant one.
Survival and recurrences
The mean follow-up time was 90 months (IQR: 81, range 3-274 months); at the end of the study period, 141 (19%) patients died. Five-and 10-year OS rates were 91% (95% CI: 0.88-0.93) and 77% (95% CI: 0.72-0.80), respectively (Fig. 1A) . Survival rates by WHO-HC in the collapsed scheme (5-year OS-A/AB 93%, early-B 90%, advanced-B 85%) showed a fairly better prognostic stratification compared with the classic one (5-year OS-A 93%, AB 93%, B1 92%, B2 90%, B3 85%) (Fig. 1B and C) .
Univariate and multivariate models for OS are given in Table 2 On multivariate analysis, Masaoka stage only (III HR: 3.09, IV HR: 15.08; P < 0.01) was an independent predictor of recurrence, although male (HR: 0.68, P = 0.09) and WHO-HC in the collapsed scheme (HR: 1.32, P = 0.16) demonstrated a weak prognostic impact (Table 3 ). In univariate Fine and Gray's models, age (HR: 0.98 per years, P = 0 .01) and male gender (HR: 0.64, P = 0.05) demonstrated significant lower risk in recurrence, while Masaoka stage (III HR: 3.44, IV HR: 23.39; P < 0.01), WHO-HC in the collapsed scheme (early-B type HR: 1.93-advanced-B HR: 4.58, P < 0.01) and preoperative treatment (HR: 4.63, P < 0.01) showed a higher risk.
WHO histological classification and variables of interest
The association between variables of interest frequencies by WHO-HC classic and collapsed schemes are illustrated in Table 4 .
Taking into account the multivariate logistic regression models, classic and collapsed schemes indicated a significant decrease of age (P < 0.01) among histological types (from A to B3). Only the collapsed scheme showed a significant association between MG and B histotypes (OR: 1.64, P < 0.01). Finally, the collapsed scheme demonstrated to be more effective than the classic WHO-HC in Masaoka stage stratification: lower stages were associated with A/AB types (P < 0.01).
DISCUSSION
Since its first introduction in clinical practice the WHO histological classification (WHO-HC) prognostic value has been evaluated by several papers [6, 7, 12] . Additionally, few authors focused on its relationships with clinical variables [13] . The primary aim of the present study was to evaluate how WHO-HC may influence long-term outcomes after thymomectomy; therefore, we also analysed correlations between patients' clinical characteristics and WHO-HC. The results of this study, performed on a large cohort of patients operated, demonstrate that: (i) in the collapsed scheme WHO-HC has a fair value in predicting local recurrence; (ii) only in the collapsed scheme WHO-HC shows a clear correlation with MG; (iii) the WHO-HC collapsed scheme confirms a significative correlation with the Masaoka staging system; (iv) WHO-HC is not suitable as an independent prognostic factor, even though the collapsed scheme demonstrated a reasonable significance in affecting survival in the univariate model.
The first histological thymoma classification was designed by Bernatz et al. in 1961 [14] . Afterwards, no classification was widely recognized for almost three decades [3, 15, 16] .
In 1999, WHO published its first thymic tumours histological classification [1] , and an updated version in 2004 [2] ; its prognostic relevance [12] was confirmed by several studies [6, 7] . In addition, many authors reported an increasingly worse prognosis from type A to B3 [17] . Occasionally, simplified or collapsed schemes were proposed, to improve the prognostic value. In 2008, a meta-analysis, which analysed the published studies on the WHO-HC clinical value [5] , suggested that WHO-HC categories could be simplified into three groups: A/AB/B1, B2 and B3, to join similar survival patterns. Likewise, Wright et al. proposed to collapse histotypes in A (A, AB), early B (B1, B2) and advanced B (B3) to better stratify prognosis [11] . On the other hand, lack of impact by WHO-HC on survival was demonstrated by other papers [8, 18] . In particular, Rieker et al. [8] reported that AB and B1 histotypes showed the most favourable outcome, while A and B2 presented worse and similar prognosis, although recent studies established no difference in survival between B2 and B3 tumour types [19] .
In our study, we merged together thymoma A and AB: these neoplasms are in fact characterized (in totality-A-or only in foci -AB-) by a spindle-or oval-shaped cell population. Concerning B types tumours, we separated those with a clear and predominant epithelial differentiation (B3 as advanced-B) from those with heavy component of lymphocytes (B1 and B2 as early-B) . Worse biological behaviour of B3 was demonstrated by several studies [4-6, 10-12, 20] , and DNA methylation [21] , loss of heterozygosis and genetic aberration [22] were also more frequently observed in B3 tumours than in other B types.
A fairly similar distribution of histological tumour subtypes was seen in our study: 275 A/AB, 337 early-B and 135 advanced-B. This homogeneity in case distribution and the large cohort of patients strengthened our results. On the other hand, the fact that our cohort of patients was retrospectively collected and included a relatively small number of events (which is in agreement with the typical indolent biological behaviour of thymoma) should be taken into account.
Concerning OS, the WHO-HC classic scheme did not demonstrate any statistical value in defining groups of worse prognosis. As previously reported, this did not represent an unusual finding and it was recently confirmed in a recent series of over 1700 cases [23] . Many authors attribute a lack of reproducibility in diagnosis to WHO-HC: this could explain the huge heterogeneity in results of published papers over the last ten years [24] .
Therefore, some authors proposed a simplified scheme for both prognostic and diagnostic purposes. In particular, Suster and Moran [25] in 2006 suggested an easier three-class classification: well (A, AB, B1 and B2), moderately (B3) and poorly differentiated TC. Additionally, Rieker et al. [8] demonstrated acceptable diagnostic reproducibility and prognostic stratification, when WHO categories were combined into three.
In our series, the proposed simplified scheme did not prove to be an independent prognostic indicator but showed a significant predictive value only on univariate analysis. Similarly, WHO-HC collapsed categories indicated a suggestive correlation with FFR in the univariate model. Although a robust statistical significance on multivariate analysis could not be observed, a strong relationship between B-types and higher Masaoka stages could be a confounding factor.
Again, the WHO-HC classic scheme was not an acceptable indicator of risk of recurrence after a complete resection.
Secondarily, our results confirm the prognostic role of Masaoka stage in OS and FFR. As in recent reviews [4] , we did not find any statistical difference between Stages I and II: consequentially, we combined them in our models. In our opinion, a possible future merging of Masaoka stages in only three classes (collapsing stages I and II) seems to be reasonable.
Incomplete surgical resection showed a worse survival only in the univariate model: a possible reason is the high correlation between R1 and R2 resection and advanced Masaoka stages. Finally, MG had no impact on both OS and FFR.
Concerning the correlations between tumour histology and clinico-pathological characteristics, we identified a trend towards WHO-HC collapsed classes: the correlation with MG, higher Masaoka stages and young age significantly increased from A/AB to advanced-B. Classic WHO-HC categories did not show any similar well-defined tendency. Interestingly, WHO classes did not demonstrate a significant correlation with final resection status: this is probably explained by the stronger association between incomplete resections and advanced tumour stages.
In conclusion, our results showed evidence of the lack of significance of WHO-HC in influencing survival and identifying risk of relapses, and its weak correlation with patients' characteristics. The proposed adoption of simplified categories improved the definition of the relationship with clinico-pathological characteristics, but its role as an indicator of independent survival or recurrence remains inadequate. 
